- Prev close
- $515.30
- Day range
- $511.73 – $523.95
IDXX rose +1.2% in a session where the Nasdaq 100 was +0.8% and the S&P 500 was -0.0%, which reads as a modest, well-supported move rather than a stock-specific warning. The durable picture is still anchored by +12.8% revenue growth, +18.4% EPS growth, and 62.5% gross margin, though the 36.1 P/E leaves limited room for error.
IDXX
IDEXX LABORATORIES INC
As of Sep 22, 2026
74/100
Looks healthyHealth ScoreWhy it moved
IDXX finished +1.2% on the session, versus the S&P 500 at -0.0% and the Nasdaq 100 at +0.8%, so the move was a little stronger than the market but not detached from it. The most likely primary driver is market/sector tone rather than company-specific news, because the day’s stock move is modest and there is no fresh operating headline in the facts; the recent insider-sale items are dated and do not describe a new business change.
Is this normal volatility
This looks like ordinary volatility for a high-quality but richly valued stock, not a sign of broken fundamentals. Revenue is still up +12.8% YoY (TTM) and +9.7% YoY in the latest quarter, EPS is up +18.4% YoY (TTM), and margins remain strong at 62.5% gross, 32.0% operating, and 25.0% net; that is a solid operating base. But valuation is demanding at 36.1 P/E, 35.6 forward PE, and PEG 3.24 — the PEG is P/E divided by growth, so 3.24 means investors are paying 3.24x the growth rate — and beta is 1.57, which helps explain why even a modest move can appear. The stock’s 52-week range is $500.61 – $769.98, and the current level sits toward the lower end of that span, which keeps the move in context as normal price variance rather than a new fundamental break.
Earnings preview
The next earnings date is not available this period, so I cannot place a specific print on the calendar. The durable expectations visible in the facts are for a business still growing at +12.8% revenue growth (TTM), +9.7% revenue growth in the latest quarter, and +18.4% EPS growth (TTM), with 62.5% gross margin and 32.0% operating margin. There is no prior post-earnings reaction data in the facts, so the market’s focus is best framed around whether IDEXX can sustain that growth rate, keep margins near 62.5% / 32.0%, and justify a 36.1 P/E and 35.6 forward PE.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track IDXX with WhyIHold
Get a plain-English explanation the next time IDEXX LABORATORIES INC makes a big move — so you know whether it's benign or worth your attention.